Application YC di BillionToOne

Summer 2017Public

BillionToOne ha partecipato a Y Combinator nel batch Summer 2017 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.

Batch YC: Summer 2017
Settore: HealthcareDiagnostics
Dimensione team: 300
Stato: Public
Lanciata: 2016

Founder

Oguzhan AtayFounder
David TsaoFounder/CTO

Cosa fa BillionToOne

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

Application YC di BillionToOne, ricostruita

Domanda per Y Combinator

BillionToOne, batch Summer 2017. Le vere domande del form, risposte da dati pubblici.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

BillionToOne

Describe what your company does in 50 characters or less.

The genetic testing platform detecting and measuring disease.

What is your company going to make? Please describe your product and what it does or will do.

We have built a DNA molecular counter that improves the resolution of cell-free DNA diagnostics by over a thousand times. Our main product, UNITY Screen, is a non-invasive prenatal test that uniquely assesses fetal risk for recessive conditions and chromosomal abnormalities from maternal blood. We are expanding this technology into liquid biopsy tests for cancer, aiming to transform how oncology care detects and monitors disease.

Where do you live now, and where would the company be based after YC?

We currently live and work in Menlo Park, CA, and would keep the company based there after YC.

Explain your decision regarding location.

We are based in Menlo Park because it provides access to top scientific talent and proximity to leading healthcare and biotech partners, which is critical for developing and refining our complex diagnostics technology.

21 risposte in più nell'application completa

Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.

Vedi domanda completa

Domande Frequenti

Questa è l'application YC reale di BillionToOne?

No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di BillionToOne (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come BillionToOne si presenterebbe a YC, non il testo che hanno inviato.

A quale batch YC apparteneva BillionToOne?

BillionToOne apparteneva al batch Summer 2017 di Y Combinator.

Chi ha fondato BillionToOne?

BillionToOne è stato fondato da Oguzhan Atay, David Tsao.

Cosa fa BillionToOne?

The genetic testing platform detecting and measuring disease.

Come leggo la ricostruzione completa della application?

Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di BillionToOne, e di ogni altro batch YC, è in YC Insights.